MTRNR2L2: A Potential Drug Target and Biomarker (G100462981)

Target Name: MTRNR2L2

NCBI ID: G100462981

MTRNR2L2

MTRNR2L2: A Potential Drug Target and Biomarker

MTRNR2L2, a gene located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Its function and regulation have been extensively studied, providing insights into the underlying mechanisms of these diseases.

The MTRNR2L2 gene encodes a non-coding RNA molecule, which has been shown to play a critical role in regulating the expression of genes in the brain. It is expressed in various tissues and cells of the body and has been associated with various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Studies have shown that MTRNR2L2 is involved in the regulation of neurotransmitter release and cell signaling, which are crucial for the function of the brain. It has been shown to regulate the release of dopamine, serotonin, and other neurotransmitters involved in mood, emotions, and learning.

MTRNR2L2 has also been shown to play a role in the regulation of pain signaling and the modulation of pain perception. It has been shown to reduce the expression of genes involved in pain signaling and enhance the expression of genes involved in pain tolerance, suggesting that it may have potential as a pain medication.

In addition to its potential role in pain signaling, MTRNR2L2 has also been shown to be involved in the regulation of inflammation and immune response. It has been shown to regulate the expression of genes involved in inflammation and immune response, which may have implications for the treatment of autoimmune diseases.

MTRNR2L2 has also been shown to be involved in the regulation of cell survival and metabolism. It has been shown to play a role in the regulation of cell survival and metabolism, which may have implications for the treatment of diseases associated with these processes, such as cancer.

In conclusion, MTRNR2L2 is a gene that has been extensively studied for its potential role in drug targeting and biomarker generation. Its function and regulation in the brain have been shown to be involved in various neurological and systemic disorders, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the implications of MTRNR2L2 as a drug target and biomarker.

Protein Name: MT-RNR2 Like 2 (pseudogene)

Functions: Plays a role as a neuroprotective and antiapoptotic factor

The "MTRNR2L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTRNR2L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets